Logo image
Intraperitoneal immunotherapy: historical perspectives and modern therapy
Journal article   Open access   Peer reviewed

Intraperitoneal immunotherapy: historical perspectives and modern therapy

W F Morano, A Aggarwal, P Love, S D Richard, J Esquivel and W B Bowne
Cancer gene therapy, v 23(11), pp 373-381
Nov 2016
PMID: 27834358
url
https://doi.org/10.1038/cgt.2016.49View
Published, Version of Record (VoR)Maybe Open Access (Publisher Bronze) Open

Abstract

Animals Antibodies, Bispecific - therapeutic use Antineoplastic Agents, Immunological - therapeutic use History, 20th Century History, 21st Century Humans Immunotherapy - history Peritoneal Neoplasms - secondary Peritoneal Neoplasms - therapy
Intraperitoneal immunotherapy represents a novel strategy for the management of peritoneal metastases (PM). Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has remained the gold standard of treatment for patients with PM, yet despite optimal treatment, recurrence rates remain high and long-term survival poor. From Coley's toxins to immune checkpoint inhibitors, the wide variety of anticancer immunotherapeutic strategies are now garnering attention for control of regional disease of the peritoneal cavity. Early studies with vaccine-based therapies, adoptive cell transfer, immune checkpoint inhibitors, and chimeric T cells with tumor-specific antigen receptors (CAR-T cells) are being performed, showing promise for control of peritoneal spread and induction of lasting anticancer immunity. In addition, catumaxomab, a trifunctional antibody, has been approved for intraperitoneal immunotherapy in Europe for the control of malignant ascites in patients with epithelial cell adhesion molecule positive cancers. We review a brief history of immunotherapy and current modalities under investigation for intraperitoneal use in the treatment of PM.

Metrics

6 Record Views
37 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#5 Gender Equality
#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Biotechnology & Applied Microbiology
Genetics & Heredity
Medicine, Research & Experimental
Oncology
Logo image